Seiko Epson Corporation has developed what it believes to be the world's first compact office papermaking system capable of producing new paper from securely shredded waste paper without the use of water. Epson plans to put the new "PaperLab" into commercial production in Japan in 2016, with sales in other regions to be decided at a later date. Businesses and government offices that install a PaperLab in a backyard area will be able to produce paper of various sizes, thicknesses, and types, from office paper and business card paper to paper that is colored and scented. A developmental prototype of the PaperLab will be demonstrated at the Epson booth (booth location: 4-002) at Eco-Products 2015 , an environmental exhibition that will take place at the Tokyo Big Sight (Tokyo International Exhibition Center) from December 10 to 12. The enduring universal appeal of paper lies in its simplicity as a communication tool. Information on the highly portable and always convenient medium of paper is easy to read, easy to digest, and easy to remember. On the other hand, this essential tool is also produced from a limited resource. As a leading company in the world of printing, Epson has been deeply involved with paper used for its printer products. With this in mind, the company set out to develop technology that would change the paper cycle. With PaperLab, Epson aims to give new value to paper and stimulate recycling. Ordinarily, paper is recycled in an extensive process that typically involves transporting waste paper from the office to a papermaking (recycling) facility. With PaperLab, Epson is looking to shorten and localize a new recycling process in the office. Until now enterprise has had to hire contractors to handle the disposal of confidential documents or has shredded them themselves. With a PaperLab, however, enterprise will be able to safely dispose of documents onsite instead of handing them over to a contractor. PaperLab breaks documents down into paper fibers, so the information on them is completely destroyed. 3. High-speed production of various types of paper PaperLab produces the first new sheet of paper in about three minutes of having loaded it with waste paper and pressing the Start button. The system can produce about 14 A4 sheets per minute and 6,720 sheets in an eight-hour day. Users can produce a variety of types of paper to meet their needs, from A4 and A3 office paper of various thicknesses to paper for business cards, color paper and even scented paper. PaperLab makes paper without the use of water. Ordinarily it takes about a cup of water to make a single A4 sheet of paper. Given that water is a precious global resource, Epson felt a dry process was needed. In addition, recycling paper onsite in the office shrinks and simplifies the recycling loop. Users can expect to purchase less new paper and reduce their transport CO₂ emissions. Epson's foundation of compact, energy-saving and high-precision technologies enables the company to achieve small, energy-efficient products that offer outstanding accuracy and performance. With printer business operations spanning the consumer, office, commercial and industrial sectors, Epson has an immense storehouse of ink and media expertise, as well as the ability to produce reliable, durable systems that will operate stably. In addition to these, Epson has developed Dry Fiber Technology without water, a new group of technologies for the PaperLab. Using an original mechanism, waste paper is transformed into long, thin cottony, fibers. This process immediately and completely destroys confidential documents. Since the PaperLab does not use water, it does not require plumbing facilities. That, plus its compact size, makes it easy to install in the backyard of an office. A variety of different binders can be added to the fiberized material to increase the binding strength or whiteness of the paper or to add color, fragrance, flame resistance, or other properties needed for a given application. Users can produce sheets of A4 or A3 office paper and even paper for business cards thanks to forming technology that allows them to control the density, thickness, and size of paper. Epson aims to help customers increase operational efficiency by providing high-speed, low-power business inkjet printers that deliver images of amazing quality at a low cost per print. And by employing PaperLab to convert used paper into new, the company believes that offices of all types will fundamentally change the way they think about paper.
News Article | February 22, 2013
Genentech’s scientists have long wondered about what would happen if they could deliver a more powerful version of their original hit antibody drug for breast cancer. Now they’ll see. The South San Francisco-based company, a unit of Roche, said today that it won FDA clearance to start selling ado-trastuzumab emtansine (Kadcyla) as a new treatment for breast cancer patients whose tumors have spread, and which overexpress the HER2 protein. The drug, long known as T-DM1, combines the targeting capability of Genentech’s original antibody called trastuzumab (Herceptin) with a toxin that gives it extra tumor-killing punch. The approval is also noteworthy for Waltham, MA-based ImmunoGen (NASDAQ: IMGN), as it licensed technology to Genentech to develop the product, and stands to collect royalties on sales. The FDA approval of Kadcyla (pronounced kad-SIGH-luh) is an important milestone for patients, for the businesses involved, and for science because of the novel way this drug works. The Genentech drug showed an ability in clinical trials to help women live longer, while causing fewer severe side effects than those who got standard treatment. The drug, priced at $9,800 a month, clearly has the potential to generate billions in annual sales for Genentech for many years to come. For scientists, it represents a major technical achievement, as it’s one of only two marketed drugs that effectively links an antibody to a toxin—the other is brentuximab vedotin (Adcetris) from Seattle Genetics (NASDAQ: SGEN). Researchers hope that these two drugs are just the beginning of a new wave of targeted, and more potent, cancer drugs. “Kadcyla is an antibody-drug conjugate representing a completely new way to treat HER2-positive metastatic breast cancer, and it helped people in the EMILIA study live nearly six months longer,” said Hal Barron, Genentech’s chief medical officer and head of global product development, in a statement. “We currently have more than 25 antibody-drug conjugates in our pipeline and hope this promising approach will help us deliver more medicines to fight other cancers in the future.” Genentech showed in its pivotal clinical trial of 991 women that patients on the new breast cancer drug lived a median time of 30.9 months, compared with 25.1 months for those who were randomly assigned to get GlaxoSmithKline’s lapatinib (Tykerb) and Roche’s chemo drug capecitabine (Xeloda). Researchers reported that about 40.8 percent of patients suffered moderate to severe side effects on the new drug, compared with 57 percent in the comparison group. Still, this is a potent cancer drug, and it does come with some significant side effects. The FDA-approved prescribing information includes a “black box” warns doctors that liver toxicity, heart toxicity and death have occurred in Kadcyla-treated patients. The drug can also cause severe life-threatening birth defects, the FDA said in a statement. The price is sure to cause some people heartache, too. At $9,800 a month, the price is more than double that of the original trastuzumab (Herceptin), which sells for $4,500 a month. Another Genentech drug approved last year for HER2-positive breast cancer, pertuzumab (Perjeta), was originally priced at $5,900 a month. Genentech spokeswoman Susan Willson said the company expects a course of therapy with Kadcyla to cost about $94,000, based on patients taking the drug for about 9.6 months. The company is also making the drug available through a patient assistance program for those who can’t afford it, she said. “People who do not have health insurance, or who have reached the lifetime limit set by their insurance company, might qualify to receive Kadcyla for free,” she said. Genentech tried once before to win FDA approval on the basis of more preliminary, Phase II clinical trial data. The company’s application was turned down in August 2010, as the agency asked for more data. The more definitive proof of Kadcyla’s value came last year in the form of the 991-patient study known as Emilia. About 232,000 women will be diagnosed with breast cancer this year, and an estimated 39,600 will die from it, the FDA said, citing data from the National Cancer Institute. For more information on the scientific odyssey this drug took to get through the R&D process, see this Xconomy feature from June 2010.
News Article | November 19, 2015
Seiko Epson Corporation has developed a new series of 6-axis (vertically articulated) industrial robots. The robots in the new N series have an innovative folding arm that will allow them to be installed in very limited spaces. The first product in the series is scheduled for global release in May 2016. Epson will demonstrate an N series robot at the International Robot Exhibition 2015, which will run from December 2-5, at Tokyo Big Sight (the Tokyo International Exhibition Center).